Herman Meurs
Herman Meurs has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Harm Maarsingh
3 shared publicationsJohan Zaagsma
3 shared publicationsLejla Macic
11Department of Molecular Pharmacology, University Centre for Pharmacy, Antonius Deusinglaan 1, Groningen, NL-9713 AV, The Netherlands
1 shared publicationMarco A M Hamer
11Department of Molecular Pharmacology, University Centre for Pharmacy, Antonius Deusinglaan 1, Groningen, NL-9713 AV, The Netherlands
1 shared publicationNiek Molendijk
11Department of Molecular Pharmacology, University Centre for Pharmacy, Antonius Deusinglaan 1, Groningen, NL-9713 AV, The Netherlands
1 shared publicationSue McKay
11Department of Molecular Pharmacology, University Centre for Pharmacy, Antonius Deusinglaan 1, Groningen, NL-9713 AV, The Netherlands
1 shared publication
Latest Publications
- 30 November 2003
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 24 (11) , 562-563
Response to Ricciardolo: The functional significance of arginase in asthma is supported by gene expression
- 30 November 2003
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 24 (11) , 562-563
Response to Ricciardolo: The functional significance of arginase in asthma is supported by gene expression
- 1 September 2003
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 24 (9) , 450-455
Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness
- 1 September 2003
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 24 (9) , 450-455
Arginase and asthma: novel insights into nitric oxide homeostasis and airway hyperresponsiveness
- 1 June 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 136 (3) , 391-398
Increased arginase activity underlies allergen‐induced deficiency of cNOS‐derived nitric oxide and airway hyperresponsiveness
A deficiency of constitutive nitric oxide synthase (cNOS)‐derived nitric oxide (NO), due to reduced availability of L‐arginine, importantly contributes to allergen‐induced airway hyperresponsiveness (AHR) after the early asthmatic reaction (EAR). Since cNOS and arginase use L‐arginine as a common substrate, we hypothesized that increased arginase activity is involved in the allergen‐induced NO deficiency and AHR. Using a guinea‐pig model of allergic asthma, we addressed this hypothesis by examining the effects of the specific arginase inhibitor Nω‐hydroxy‐nor‐L‐arginine (nor‐NOHA) on the responsiveness to methacholine of isolated perfused tracheae from unchallenged control animals and from animals 6 h after ovalbumin challenge. Arginase activity in these preparations was investigated by measuring the conversion of L‐[14C]arginine to [14C]urea. Airways from allergen‐challenged animals showed a 2 fold (PPω‐nitro‐L‐arginine methyl ester (L‐NAME, 0.1 mM, IL), while L‐NAME had no further effect on the airways from challenged animals. Remarkably, 5 μM nor‐NOHA (IL) normalized the hyperresponsiveness of challenged airways to basal control (PPPBritish Journal of Pharmacology (2002) 136, 391–398; doi:10.1038/sj.bjp.0704725
- 1 June 2002
- Published by Wiley in British Journal of Pharmacology
- Vol. 136 (3) , 391-398
Increased arginase activity underlies allergen‐induced deficiency of cNOS‐derived nitric oxide and airway hyperresponsiveness
A deficiency of constitutive nitric oxide synthase (cNOS)‐derived nitric oxide (NO), due to reduced availability of L‐arginine, importantly contributes to allergen‐induced airway hyperresponsiveness (AHR) after the early asthmatic reaction (EAR). Since cNOS and arginase use L‐arginine as a common substrate, we hypothesized that increased arginase activity is involved in the allergen‐induced NO deficiency and AHR. Using a guinea‐pig model of allergic asthma, we addressed this hypothesis by examining the effects of the specific arginase inhibitor Nω‐hydroxy‐nor‐L‐arginine (nor‐NOHA) on the responsiveness to methacholine of isolated perfused tracheae from unchallenged control animals and from animals 6 h after ovalbumin challenge. Arginase activity in these preparations was investigated by measuring the conversion of L‐[14C]arginine to [14C]urea. Airways from allergen‐challenged animals showed a 2 fold (PPω‐nitro‐L‐arginine methyl ester (L‐NAME, 0.1 mM, IL), while L‐NAME had no further effect on the airways from challenged animals. Remarkably, 5 μM nor‐NOHA (IL) normalized the hyperresponsiveness of challenged airways to basal control (PPPBritish Journal of Pharmacology (2002) 136, 391–398; doi:10.1038/sj.bjp.0704725